Vinva Investment Management Ltd Sells 18,166 Shares of Bristol-Myers Squibb (NYSE:BMY)

Vinva Investment Management Ltd decreased its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 13.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 113,935 shares of the biopharmaceutical company's stock after selling 18,166 shares during the period. Vinva Investment Management Ltd's holdings in Bristol-Myers Squibb were worth $6,387,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Compass Ion Advisors LLC purchased a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $210,000. Enhancing Capital LLC purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $2,110,000. Xponance Inc. increased its holdings in shares of Bristol-Myers Squibb by 3.5% in the fourth quarter. Xponance Inc. now owns 333,939 shares of the biopharmaceutical company's stock worth $18,888,000 after purchasing an additional 11,370 shares during the last quarter. Boston Partners increased its stake in Bristol-Myers Squibb by 15.8% in the 4th quarter. Boston Partners now owns 3,890,966 shares of the biopharmaceutical company's stock worth $220,088,000 after acquiring an additional 529,575 shares during the last quarter. Finally, Generali Asset Management SPA SGR purchased a new stake in Bristol-Myers Squibb during the fourth quarter valued at $16,061,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BMY shares. Truist Financial increased their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. Citigroup increased their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Cantor Fitzgerald lifted their price objective on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Finally, Bank of America reissued a "neutral" rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $57.86.

Remove Ads

Bristol-Myers Squibb Trading Up 1.1 %

Shares of NYSE BMY traded up $0.64 during trading hours on Friday, reaching $61.06. The stock had a trading volume of 25,864,960 shares, compared to its average volume of 12,181,935. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The firm has a market cap of $123.92 billion, a price-to-earnings ratio of -13.82, a P/E/G ratio of 2.07 and a beta of 0.43. The business's fifty day moving average price is $58.17 and its two-hundred day moving average price is $55.93. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.06%. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.

Insider Activity

In related news, EVP Samit Hirawat bought 1,823 shares of the stock in a transaction on Friday, February 14th. The stock was bought at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.